%0 Journal Article %1 S?awek2003 %A S?awek, J. %A Klimont, L. %D 2003 %J Eur J Neurol %K Botulinum Toxin Type A; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Injections, Intramuscular; Male; Motor Activity; Movement; Neuromuscular Agents; Outcome Assessment (Health Care); Prospective Studies; Range of Motion, Articular; Time Factors %N 3 %P 313--317 %T Functional improvement in cerebral palsy patients treated with botulinum toxin A injections - preliminary results. %V 10 %X Authors report the preliminary results of an open-label, prospective study to evaluate a functional benefit of botulinum toxin type A injections in diparetic cerebral palsy patients, using gross motor function measure (GMFM) score. In a group of 14 children (mean age 3.9 years, range 2-6) treated with Dysport 30 IU/kg, a statistically significant improvement (P < 0.05) was noticed in both simple measurements (Modified Ashworth Scale, Selective Motor Control, Passive Range of Movements, Physician Rating Scale and parental Clinical Global Impression) and complex functions (GMFM dimensions D and E) after 1 and 3 months. However, the simple measurement scores decreased (but not to the baseline) after 3 months; surprisingly, GMFM scores were still increasing (7.7\% change after 3 months and 11.3\% change after 6 months in nine patients). These results are in concordance with a few other data published to date. The study may support the concept of persistent functional gain in long-term treatment of spasticity caused by cerebral palsy with botulinum toxin type A.

@article{S?awek2003, abstract = {Authors report the preliminary results of an open-label, prospective study to evaluate a functional benefit of botulinum toxin type A injections in diparetic cerebral palsy patients, using gross motor function measure (GMFM) score. In a group of 14 children (mean age 3.9 years, range 2-6) treated with Dysport 30 IU/kg, a statistically significant improvement (P < 0.05) was noticed in both simple measurements (Modified Ashworth Scale, Selective Motor Control, Passive Range of Movements, Physician Rating Scale and parental Clinical Global Impression) and complex functions (GMFM dimensions D and E) after 1 and 3 months. However, the simple measurement scores decreased (but not to the baseline) after 3 months; surprisingly, GMFM scores were still increasing (7.7\% change after 3 months and 11.3\% change after 6 months in nine patients). These results are in concordance with a few other data published to date. The study may support the concept of persistent functional gain in long-term treatment of spasticity caused by cerebral palsy with botulinum toxin type A.}, added-at = {2014-07-19T21:12:02.000+0200}, author = {S?awek, J. and Klimont, L.}, biburl = {https://www.bibsonomy.org/bibtex/24fd8230d098929c8abcedb8a4b4d0f5d/ar0berts}, groups = {public}, interhash = {a0b58c9e060ba5867c1fb6d31c926182}, intrahash = {4fd8230d098929c8abcedb8a4b4d0f5d}, journal = {Eur J Neurol}, keywords = {Botulinum Toxin Type A; Cerebral Palsy; Child; Child, Preschool; Female; Humans; Injections, Intramuscular; Male; Motor Activity; Movement; Neuromuscular Agents; Outcome Assessment (Health Care); Prospective Studies; Range of Motion, Articular; Time Factors}, month = May, number = 3, pages = {313--317}, pii = {582}, pmid = {12752407}, timestamp = {2014-07-19T21:12:02.000+0200}, title = {Functional improvement in cerebral palsy patients treated with botulinum toxin A injections - preliminary results.}, username = {ar0berts}, volume = 10, year = 2003 }